Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The identification of a gatekeeper mutation also suggests
2021-01-26

The identification of a gatekeeper LX-1031 also suggests that alternative DDR2 inhibitors may be required to overcome acquired resistance. Additional DDR2 inhibitors that have been isolated include the recently identified alkaloid natural products discoipyrroles A-D and the chemotherapeutic Actinom
-
In this study cell migration in response to LTD
2021-01-26

In this study, cell migration in response to LTD4 exhibited a typical bell-shaped dose-response curve with optimal activity at 10 nM. However, the effect of inhaled CysLTs on airway inflammatory cells in vivo has not been widely reported to date, therefore, the role of CysLTs in the development of a
-
Ruxolitinib phosphate There are numerous resources clinician
2021-01-26

There are numerous resources clinicians may use to gather information on the strength of evidence related to pharmacogenetic-based dosing and treatment decisions, as well as specific dosing guidelines, some of which are summarized in this review. These include resources from CPIC, which provides pee
-
On the basis of the findings described above a series
2021-01-26

On the basis of the findings described above, a series of heterotricyclic analogs were designed and synthesized. The human CRF1 receptor binding and antagonist activity data for newly designed heterotricyclic core antagonists 28–33 are described in Table 3. Most of the tricyclic core analogs listed
-
All of the studies referred
2021-01-26

All of the studies referred to above were on microvillous membrane from hSTB; however, there is little information regarding conductances in the basal membrane. Illsley and Sellers, using a fluorescent technique, determined the relative permeabilities of cations and chloride in basal membrane vesicl
-
Fisetin tetrahydroxyflavone is a flavonol present in several
2021-01-26

Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a flavonol present in several fruits and vegetables such as grape, persimmon, strawberry, apple, and onion at concentrations rangeing from 2 to 160 μg/g. Fisetin is a well–known bioflavonoid with remarkable biological effects including chemopreventive/chemo
-
br Thy nephritis is one
2021-01-26

Thy1.1 nephritis is one of the most commonly used models to study the course of immunoglobulin A and other mesangioproliferative nephropathies. To date, most of the studies have focused on mesangial and, to a lesser extent, endothelial cell recovery following capillary damage, whereas data concern
-
Immature and mature B cells adapt
2021-01-26

Immature and mature all trans retinal adapt differently to signal transduction via BCR [2]. This functional dichotomy is also regulated by noncytokine substances in the surroundings of mature and immature B lymphocytes, such as the prostanoid family of lipid mediators including PGD2, PGE2, PGF2α, P
-
The following are the supplementary data related to this
2021-01-26

The following are the supplementary data related to this article. Acknowledgments Introduction Cyclooxygenases metabolize arachidonic Nitecapone australia to five primary prostanoids, PGE2, PGF2, PGI2, TXA2 (TX), and PGD2. These lipid mediators interact with specific members of a family of di
-
The MOF system described by Farha and coworkers combines rat
2021-01-26

The MOF system described by Farha and coworkers combines rational design of the support and good experimental results regarding activity and stability. However, a further increase in the speed of enzyme loading into the MOF and a decrease in leaching are still required. How can the design rules prop
-
br Concluding remarks and prospective Cardiac proteinopathy
2021-01-26

Concluding remarks and prospective Cardiac proteinopathy, a more common disease condition and more frequent cause of cardiomyocyte decay than previously thought, is largely neglected and no effective therapy exists yet. Protein quality control and protein degradation via autophagy or the ubiquiti
-
The DNA damage response DDR is a cellular mechanism that
2021-01-25

The DNA damage response (DDR) is a cellular mechanism that protects against DNA damage induced by endogenous and exogenous factors, it includes changes in cellular processes such as Cy3-UTP regulation, DNA damage repair, apoptosis and chromatin remodeling. In recent years, the DDR has been recogniz
-
In most cases patients will not
2021-01-25

In most cases, patients will not present immediately after SM exposure because SM-induced clinical symptoms typically occur after a latency period of several hours [8], [9], [10]. When they do present, the detection of free, unbound alkylating agent is highly unlikely. For this reason, available rap
-
In this review focusing on
2021-01-25

In this review, focusing on biocatalyst “formate dehydrogenase FDH” catalyzing both of the formic Pyocyanin oxidation to CO2 and the CO2 reduction to formic acid, representative examples of properties, types, structure of active-site of FDH and, reaction mechanism of formic acid oxidation and CO2 r
-
br Acknowledgement br Introduction Recent developments
2021-01-25

Acknowledgement Introduction Recent developments in cancer immunotherapies have demonstrated durable responses, suggesting that effective immunotherapy would hold promise to improve patient outcome (Gunturu et al., 2013; Hodi et al., 2003; Lutz et al., 2011; Ribas et al., 2009). However, attem
16626 records 765/1109 page Previous Next First page 上5页 761762763764765 下5页 Last page